Trials / Completed
CompletedNCT04861090
A Study in Teenagers and Adults With Hereditary Angioedema (HAE) Type I or Type II Who Use Lanadelumab as Long-Term Prophylaxis
Retrospective, Observational Chart Review Study Evaluating Clinical Effectiveness and Disease/Treatment Management Among Patients Who Initiated Long-term Prophylaxis With Takhzyro® in a Real-world Setting
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 207 (actual)
- Sponsor
- Takeda · Industry
- Sex
- All
- Age
- 12 Years
- Healthy volunteers
- Not accepted
Summary
The main aims of this study are to learn how many people with HAE Type I or Type II are attack-free when treated with lanadelumab in real life. This includes the number of people that are attack-free when lanadelumab is given every 2 and every 4 weeks. This study is about collecting existing data only; participants will not receive lanadelumab as part of this study. No new information will be collected during this study. Only data already available at the participant's doctor's office will be reviewed and collected for this study. Participants do not need to visit their doctor in addition to their normal visits.
Conditions
Timeline
- Start date
- 2021-09-15
- Primary completion
- 2022-06-30
- Completion
- 2022-06-30
- First posted
- 2021-04-27
- Last updated
- 2023-01-13
Locations
20 sites across 4 countries: Austria, France, Germany, Greece
Source: ClinicalTrials.gov record NCT04861090. Inclusion in this directory is not an endorsement.